A61K 2039/525
Virus
Official title: {Virus}
A61K2039/525 (Virus) appears on 4,824 US grants and 7,001 published applications in this corpus.
Search patents in A61K- Granted patents
- 4,824
- Published applications
- 7,001
- Assignees
- 2,251
- Inventors
- 10,214
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 18 | 0 |
| 1977 | 17 | 0 |
| 1978 | 10 | 0 |
| 1979 | 6 | 0 |
| 1980 | 7 | 0 |
| 1981 | 10 | 0 |
| 1982 | 13 | 0 |
| 1983 | 1 | 0 |
| 1984 | 7 | 0 |
| 1985 | 20 | 0 |
| 1986 | 12 | 0 |
| 1987 | 22 | 0 |
| 1988 | 11 | 0 |
| 1989 | 6 | 0 |
| 1990 | 8 | 0 |
| 1991 | 18 | 0 |
| 1992 | 14 | 0 |
| 1993 | 12 | 0 |
| 1994 | 8 | 0 |
| 1995 | 14 | 0 |
| 1996 | 22 | 0 |
| 1997 | 44 | 0 |
| 1998 | 86 | 0 |
| 1999 | 70 | 0 |
| 2000 | 86 | 0 |
| 2001 | 74 | 22 |
| 2002 | 74 | 119 |
| 2003 | 99 | 224 |
| 2004 | 81 | 252 |
| 2005 | 74 | 244 |
| 2006 | 102 | 219 |
| 2007 | 121 | 221 |
| 2008 | 122 | 247 |
| 2009 | 148 | 280 |
| 2010 | 171 | 360 |
| 2011 | 162 | 339 |
| 2012 | 151 | 281 |
| 2013 | 147 | 266 |
| 2014 | 219 | 271 |
| 2015 | 189 | 266 |
| 2016 | 211 | 293 |
| 2017 | 257 | 321 |
| 2018 | 258 | 306 |
| 2019 | 244 | 336 |
| 2020 | 249 | 328 |
| 2021 | 236 | 354 |
| 2022 | 213 | 325 |
| 2023 | 186 | 349 |
| 2024 | 190 | 341 |
| 2025 | 184 | 272 |
| 2026 | 120 | 165 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Lipidated FLIPr and uses thereof in vaccine6 Oct 2026US 12,752,003 B2National Health Research Institutes
- Ambient temperature lipid particle storage systems and methods29 Sep 2026US 12,746,281 B2Ambient Biosciences, Inc.
- Recombinant modified vaccinia virus (MVA) vaccine against coronavirus disease29 Sep 2026US 12,746,282 B2Bavarian Nordic A/S
- C-terminus modified human papilloma virus type 6 L1 protein and use thereof22 Sep 2026US 12,741,016 B2Chinese Academy of Medical Sciences
- Oncolytic virus in combination with immune checkpoint inhibitor for treating tumors15 Sep 2026US 12,734,202 B2Joint Biosciences (Sh) Ltd.
- Inhaled adenovirus vector vaccine, preparation method therefor and use thereof8 Oct 2026US 2026/0306605 A1Cansino Biologics Inc.
- Treating a type i interferon upregulation or aberrant il-33 upregulation disease or condition with polyomavirus8 Oct 2026US 2026/0306609 A1The General Hospital Corporation
- Method for inducing an immune response8 Oct 2026US 2026/0306617 A1Acclarent, Inc.
- Natural attenuated strain of infectious laryngotracheitis virus with good safety and good immunogenicity and use thereof8 Oct 2026US 2026/0306619 A1Institute of Animal Husbandry and Veterinary Medicine, Fujian Academy of Agricultural Sciences
- Dengue virus serotype-specific modulation of t cell responses8 Oct 2026US 2026/0306621 A1The United States Government as represented by the Department of Veterans Affairs
Most cited
By later US patents
- Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site1,449US 7,718,180 B22010
- Methods for treatment of cancer368US 8,906,682 B2The Trustees of the University of Pennsylvania · 2014
- Compositions for treatment of cancer277US 8,911,993 B2The Trustees of the University of Pennsylvania · 2014
- Recombinant negative strand RNA virus expression-systems218US 5,166,057 AMount Sinai School of Medicine of the City University of New York · 1992
- Methods for treatment of cancer216US 8,916,381 B1The Trustees of the University of Pennyslvania · 2014